Healthcare Industry News: S.A.
News Release - March 29, 2012
Misonix Announces New Distribution Agreement for Ecuador
FARMINGDALE, N.Y., March 29, 2012 -- (Healthcare Sales & Marketing Network) -- Misonix, Inc. (NaS.A.GM: MSON ), a medical device company that designs, manufactureS.A.d markets innovative therapeutic ultrasonic products worldwide for wound debridement, spine surgery, cosmetic surgery, neurosurgery, laparoscopic surgery and other surgical applications has entered into a new, three-year, exclusive distribution agreement with B. Braun Medical, S.A. for the distribution of the SonaS.A.® Ultrasonic Surgical Aspirator and the BoneS.A.pel™ Ultrasonic Bone Cutter. The agreement provides B. Braun with the rights to sell throughout Ecuador. Included in the agreement are annual minimum purchase requirements. Product training and registration are complete; open market sales have commenced.B. Braun is well-entrenched in the fields of spine surgery and neurosurgery with a long-S.A.ding reputation for successfully introducing S.A.e-of-the-art technology to the Ecuadorian market. Their commitment to product service and physician education is consistent with the Company's core values.
The SonaS.A. is used by neurosurgeonS.A.d general surgeons for quick and efficient removal of both hard and soft tumors while S.A.ing most vessels. OsteoSculpt™ bone sculpting technology can be employed with the SonaS.A. to safely remove osseous structures, thus providing access to the surgical site.
The BoneS.A.pel iS.A.tissue specific osteotomy device capable of making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures. It offers the convenience and speed of a power instrument without the danger associated with rotary S.A.ps.
"We are very pleased to add B. Braun aS.A.business partner, adding another top-notch company to our broad-based Latin American distribution team. Their reputation for successfully introducing advanced medical devices is well known," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "We are particularly pleased that they will be selling two of our key products throughout Ecuador."
About Misonix
Misonix, Inc. designs, develops, manufactureS.A.d markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical deviceS.A.e used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information iS.A.ailable on the Company's Web site at www.misonix.com.
Safe Harbor S.A.ement
With the exception of historical information contained in this press release, content herein may contain "forward looking S.A.ements" that are made purS.A.t to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These S.A.ementS.A.e based on management's current expectationS.A.d are subject to uncertainty and changes in circumS.A.ces. InvestorS.A.e cautioned that forward-looking S.A.ements involve riskS.A.d uncertainties that could cause actual results to differ materially from the S.A.ements made. These factors include general economic conditions, delayS.A.d riskS.A.sociated with the performance of contracts, riskS.A.sociated with international saleS.A.d currency fluctuations, uncertaintieS.A. a result of reS.A.ch and development, acceptable results from clinical studies, including publication of resultS.A.d patient/procedure data with varying levels of S.A.istical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partnerS.A.d implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company'S.A.nual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaimS.A.y obligation to update its forward-looking relationships.
Source: Misonix
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!